{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-023689","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.470506+00:00","generated_at":"2026-05-17T23:54:31.566141+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GeoVax Q2 net loss $5.4M; cash $3.1M; BARDA contract terminated; GEO-MVA gets EU guidance","bullets":["Net loss $5.37M ($0.35/share) vs $5.06M ($1.99/share) in Q2 2024; per-share loss down on share dilution.","Revenue from BARDA/RRPV contract $852k; BARDA terminated contract for convenience in Q2.","Cash $3.09M at June 30; completed July 2025 public offering netting ~$5.6M.","GEO-MVA received favorable EMA guidance allowing single Phase 3 immuno-bridging trial; trial expected 2H 2026.","GEO-CM04S1 showed superior T-cell responses vs mRNA in CLL; mRNA arm failed endpoint, enrollment restricted to GEO-CM04S1."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-023689","json":"https://secwatch.observer/filing/0001437749-25-023689.json","markdown":"https://secwatch.observer/filing/0001437749-25-023689.md","text":"https://secwatch.observer/filing/0001437749-25-023689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/0001437749-25-023689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/govx20250725_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:54:31.566141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}